Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All casirivimab/imdevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Oxygen therapy -21% Improvement Relative Risk Severe case -1% Hospitalization 14% Casirivimab/i..  Williams et al.  EARLY TREATMENT Is early treatment with casirivimab/imdevimab beneficial for COVID-19? Retrospective 764 patients in the USA Study underpowered to detect differences c19early.org Williams et al., American J. Obstetric.., Sep 2022 Favors casirivimab/im.. Favors control

Effectiveness of REGEN-COV combination monoclonal antibody infusion to reduce risk of COVID-19 hospitalization in pregnancy: A retrospective cohort study

Williams et al., American Journal of Obstetrics and Gynecology, doi:10.1016/j.ajog.2022.09.017
Sep 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
16th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.000018 from 28 studies, recognized in 42 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 764 pregnant patients with COVID-19 in the USA, 88 treated with casirivimab/imdevimab, showing no significant difference in outcomes.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants Haars, Liu, Pochtovyi, Sheward, Tatham, VanBlargan.
risk of oxygen therapy, 20.8% higher, RR 1.21, p = 0.87, treatment 1 of 88 (1.1%), control 6 of 676 (0.9%), odds ratio converted to relative risk.
risk of severe case, 1.0% higher, RR 1.01, p = 0.99, treatment 1 of 88 (1.1%), control 7 of 676 (1.0%), odds ratio converted to relative risk.
risk of hospitalization, 13.9% lower, RR 0.86, p = 0.90, treatment 1 of 88 (1.1%), control 8 of 676 (1.2%), NNT 2125, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Williams et al., 12 Sep 2022, retrospective, USA, peer-reviewed, 6 authors. Contact: frank.williams2@ochsner.org.
This PaperCasirivimab/i..All
Effectiveness of REGEN-COV combination monoclonal antibody infusion to reduce the risk of COVID-19 hospitalization in pregnancy: a retrospective cohort study
MD/MPH Frank B Williams, MD John A Morgan, MPH Ardem Elmayan, MD Jane K Martin, MD Naiha Mussarat, MD Joseph R Biggio
American Journal of Obstetrics and Gynecology, doi:10.1016/j.ajog.2022.09.017
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Halalau, Imam, Karabon, External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients, Ann Med, doi:10.1080/07853890.2020.1828616
Jamieson, Rasmussen, An update on COVID-19 and pregnancy, Am J Obstet Gynecol, doi:10.1016/j.ajog.2021.08.054
Kalafat, Prasad, Birol, An internally validated prediction model for critical COVID-19 infection and intensive care unit admission in symptomatic pregnant women, Am J Obstet Gynecol, doi:10.1016/j.ajog.2021.09.024J
Weinreich, Sivapalasingam, Norton, REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2108163
{ 'DOI': '10.1016/j.ajog.2022.09.017', 'ISSN': ['0002-9378'], 'URL': 'http://dx.doi.org/10.1016/j.ajog.2022.09.017', 'alternative-id': ['S0002937822007414'], 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Effectiveness of REGEN-COV combination monoclonal antibody infusion to reduce ' 'risk of COVID-19 hospitalization in pregnancy: A retrospective cohort study'}, { 'label': 'Journal Title', 'name': 'journaltitle', 'value': 'American Journal of Obstetrics and Gynecology'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': 'https://doi.org/10.1016/j.ajog.2022.09.017'}, {'label': 'Content Type', 'name': 'content_type', 'value': 'simple-article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2022 Elsevier Inc. All rights reserved.'}], 'author': [ {'affiliation': [], 'family': 'Williams', 'given': 'Frank B.', 'sequence': 'first'}, {'affiliation': [], 'family': 'Morgan', 'given': 'John A.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Elmayan', 'given': 'Ardem', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Martin', 'given': 'Jane K.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mussarat', 'given': 'Naiha', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Biggio', 'given': 'Joseph R.', 'sequence': 'additional'}], 'container-title': 'American Journal of Obstetrics and Gynecology', 'container-title-short': 'American Journal of Obstetrics and Gynecology', 'content-domain': { 'crossmark-restriction': True, 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.com.au', 'clinicalkey.es', 'ajog.org', 'clinicalkey.com', 'elsevier.com', 'sciencedirect.com']}, 'created': {'date-parts': [[2022, 9, 12]], 'date-time': '2022-09-12T05:41:25Z', 'timestamp': 1662961285000}, 'deposited': { 'date-parts': [[2022, 9, 12]], 'date-time': '2022-09-12T14:24:59Z', 'timestamp': 1662992699000}, 'indexed': {'date-parts': [[2022, 9, 12]], 'date-time': '2022-09-12T14:50:04Z', 'timestamp': 1662994204650}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2022, 9]]}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 9, 1]], 'date-time': '2022-09-01T00:00:00Z', 'timestamp': 1661990400000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0002937822007414?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0002937822007414?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'prefix': '10.1016', 'published': {'date-parts': [[2022, 9]]}, 'published-print': {'date-parts': [[2022, 9]]}, 'publisher': 'Elsevier BV', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0002937822007414'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Obstetrics and Gynecology'], 'subtitle': [], 'title': 'Effectiveness of REGEN-COV combination monoclonal antibody infusion to reduce risk of COVID-19 ' 'hospitalization in pregnancy: A retrospective cohort study', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit